Clinical Cancer Research · 2016 · 92 citations · 35 references
MedicineCell BiologyOncologyMolecular OncologyStem Cell BiologyTumor ProgressionCancer ProgressionCancer Stem Cell BiologyCancer Stem Cell MaintenanceCancer Stem CellsProstate CancerStem Cell TumorigenicityCancer Stem Cell - Mediated ResistanceCancer Stem Cell ClonalityCancer Stem Cell ModelsCancer Stem-like CellsCastration-resistant Prostate Cancer TherapyProstate Stem Cell BiologySphere Formation AssaysTherapy-resistant Cancer Stem Cells
PURPOSE: We have shown that the phenotypically undifferentiated (PSA(-/lo)) prostate cancer cell population harbors long-term self-renewing cancer stem cells (CSC) that resist castration, and a subset of the cells within the PSA(-/lo) population bearing the ALDH(hi)CD44(+)α2β1(+) phenotype (Triple Marker(+)/TM(+)) is capable of robustly initiating xenograft tumors in castrated mice. The goal of the current project is to further characterize the biologic properties of TM(+) prostate cancer cell population, particularly in the context of initiating and propagating castration-resistant prostate cancer (CRPC). EXPERIMENTAL DESIGN: The in vivo CSC activities were measured by limiting-dilution serial tumor transplantation assays in both androgen-dependent and androgen-independent prostate cancer xenograft models. In vitro clonal, clonogenic, and sphere-formation assays were conducted in cells purified from xenograft and patient tumors. qPCR, Western blot, lentiviral-mediated gene knockdown, and human microRNA arrays were performed for mechanistic studies. RESULTS: By focusing on the LAPC9 model, we show that the TM(+) cells are CSCs with both tumor-initiating and tumor-propagating abilities for CRPC. Moreover, primary patient samples have TM(+) cells, which possess CSC activities in "castrated" culture conditions. Mechanistically, we find that (i) the phenotypic markers are causally involved in CRPC development; (ii) the TM(+) cells preferentially express castration resistance and stem cell-associated molecules that regulate their CSC characteristics; and (iii) the TM(+) cells possess distinct microRNA expression profiles and miR-499-5p functions as an oncomir. CONCLUSIONS: Our results define the TM(+) prostate cancer cells as a population of preexistent stem-like cancer cells that can both mediate and propagate CRPC and highlight the TM(+) cell population as a therapeutic target. Clin Cancer Res; 22(17); 4505-16. ©2016 AACR.
35
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2015 · 11.9K citations · Full text
Prospective Identification of Tumorigenic Prostate Cancer Stem Cells
Anne T. Collins, Paul A. Berry, Catherine Hyde et al. · Cancer Research · 2005 · 2.8K citations
Medicine, Cell Biology, Oncology +17
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen, Derek S. Welsbie, Chris Tran et al. · Nature Medicine · 2003 · 2.3K citations
Medicine, Endocrinology, Urology +17
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Can Liu, Kevin Kelnar, Bigang Liu et al. · Nature Medicine · 2011 · 1.4K citations · Full text